BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab - BeiGene Australia

Australia
- Australia
- Canada EN|FR
- China
- Germany
- Global
- Spain
- US

https://ir.beigene.com/news-details/?id=be948e49-cfb1-44bf-b8b7-23f9be5d4942

You will be redirected to

Click the link above to continue or CANCEL